Stock Research Monitor: CALA, CARA, and CLDX
LONDON, UK / ACCESSWIRE / June 21, 2018 / If you want a free Stock Review on CELG sign up now at www.wallstequities.com/registration. This morning's research on WallStEquities.com is dedicated to the Biotechnology sector, which harnesses biological processes to create technologies and products for a wide variety of challenges - from expanding crop sizes to treating disease. Four stocks have been lined up for today's assessment, and they are: Calithera Biosciences Inc. (NASDAQ: CALA), Cara Therapeutics Inc. (NASDAQ: CARA), Celgene Corp. (NASDAQ: CELG), and Celldex Therapeutics Inc. (NASDAQ: CLDX). All you have to do is sign up today for this free limited time offer by clicking the link below.
Shares in South San Francisco, California headquartered Calithera Biosciences Inc. jumped 5.53%, ending Wednesday's trading session at $5.25. The stock recorded a trading volume of 552,298 shares, which was higher than its three months average volume of 426,620 shares. The Company's shares have gained 0.96% in the last month. The stock is trading 8.01% below its 50-day moving average. Moreover, shares of Calithera Biosciences, which focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the US, have a Relative Strength Index (RSI) of 49.68. Get the full research report on CALA for free by clicking below at:
Stamford, Connecticut headquartered Cara Therapeutics Inc.'s stock rose slightly by 0.12%, closing the day at $16.64 with a total trading volume of 500,738 shares. The Company's shares have advanced 42.22% in the past month and 35.06% in the previous three months. The stock is trading 20.03% and 25.33% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Cara Therapeutics, which focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the US, have an RSI of 63.16.
On May 23rd, 2018, Cara Therapeutics announced that it has licensed worldwide rights - except in the US, Japan, and South Korea - to commercialize KORSUVA (CR845/difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in dialysis patients to Vifor Fresenius Medical Care Renal Pharma Ltd, a joint company of Vifor Pharma Group and Fresenius Medical Care that specializes in treatments for CKD. Access the free research report on CARA now by signing up at:
On Wednesday, shares in Summit, New Jersey headquartered Celgene Corp. recorded a trading volume of 5.53 million shares. The stock ended the day 0.42% higher at $79.77. The Company's shares have advanced 6.80% in the past month. The stock is trading below its 50-day moving average by 4.10%. Furthermore, shares of Celgene, which engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide, have an RSI of 48.95.
On June 18th, 2018, research firm Standpoint Research upgraded the Company's stock rating from 'Hold' to 'Buy'.
On June 19th, 2018, Celgene announced the appointment of Jonathan Biller as Executive Vice President and General Counsel, effective July 03rd, 2018. Mr. Biller will be responsible for global legal strategy and will serve on the Company's Executive Committee. He will succeed Gerald F. Masoudi, Executive Vice President and General Counsel since 2015. Are you already registered with Wall St. Equities? Do so now for free, and get the report on CELG at:
Hampton, New Jersey headquartered Celldex Therapeutics Inc.'s stock dropped 1.17%, finishing yesterday's session at $0.58. A total volume of 3.82 million shares was traded, which was above their three months average volume of 3.47 million shares. The Company's shares are trading below their 50-day moving average by 27.85%. Additionally, shares of Celldex Therapeutics, which focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics, have an RSI of 37.55.
On June 02nd, 2018, Celldex Therapeutics presented two programs at the 2018 American Society of Clinical Oncology Annual Meeting in Chicago. First was data from the Phase-1/2 study of varlilumab, a CD27 targeting investigational immune-activating antibody, and Bristol-Myers Squibb's Opdivo® (nivolumab), an anti-PD1 immunotherapy, for patients with ovarian cancer and colorectal cancer. Second was an overview of the Phase-2 study of the anti-ErbB3 antibody CDX-3379, in combination with Erbitux®, in advanced head and neck squamous cell cancer. Aspiring Member, please take a moment to register below for your free research report on CLDX at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St Equities